Verstockt B - Search Results

1

Microbiota, not host origin drives ex vivo intestinal epithelial responses.

Arnauts K, Sudhakar P, Verstockt S, Lapierre C, Potche S, Caenepeel C, Verstockt B, Raes J, Vermeire S, Sabino J, Verfaillie C, Ferrante M. Arnauts K, et al. Among authors: verstockt s, verstockt b. Gut Microbes. 2022 Jan-Dec;14(1):2089003. doi: 10.1080/19490976.2022.2089003. Gut Microbes. 2022. PMID: 35758256 Free PMC article.

2

A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.

Billiet T, Papamichael K, de Bruyn M, Verstockt B, Cleynen I, Princen F, Singh S, Ferrante M, Van Assche G, Vermeire S. Billiet T, et al. Among authors: verstockt b. J Crohns Colitis. 2015 Dec;9(12):1120-6. doi: 10.1093/ecco-jcc/jjv156. Epub 2015 Sep 7. J Crohns Colitis. 2015. PMID: 26351386

3

Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease.

Verstockt B, Van Assche G, Vermeire S, Ferrante M. Verstockt B, et al. Expert Opin Biol Ther. 2017 Jan;17(1):31-47. doi: 10.1080/14712598.2017.1258399. Epub 2016 Nov 18. Expert Opin Biol Ther. 2017. PMID: 27817215 Review.

4

Epithelial organoid cultures from patients with ulcerative colitis and Crohn's disease: a truly long-term model to study the molecular basis for inflammatory bowel disease?

Noben M, Verstockt B, de Bruyn M, Hendriks N, Van Assche G, Vermeire S, Verfaillie C, Ferrante M. Noben M, et al. Among authors: verstockt b. Gut. 2017 Dec;66(12):2193-2195. doi: 10.1136/gutjnl-2016-313667. Epub 2017 Feb 3. Gut. 2017. PMID: 28159838 No abstract available.

5

A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.

Verstockt B, Deleenheer B, Van Assche G, Vermeire S, Ferrante M. Verstockt B, et al. Expert Opin Drug Saf. 2017 Jul;16(7):809-821. doi: 10.1080/14740338.2017.1338273. Epub 2017 Jun 9. Expert Opin Drug Saf. 2017. PMID: 28573876 Review.

6

New treatment options for inflammatory bowel diseases.

Verstockt B, Ferrante M, Vermeire S, Van Assche G. Verstockt B, et al. J Gastroenterol. 2018 May;53(5):585-590. doi: 10.1007/s00535-018-1449-z. Epub 2018 Mar 19. J Gastroenterol. 2018. PMID: 29556726 Free PMC article. Review.

7

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases.

Dreesen E, Verstockt B, Bian S, de Bruyn M, Compernolle G, Tops S, Noman M, Van Assche G, Ferrante M, Gils A, Vermeire S. Dreesen E, et al. Among authors: verstockt b. Clin Gastroenterol Hepatol. 2018 Dec;16(12):1937-1946.e8. doi: 10.1016/j.cgh.2018.04.040. Epub 2018 Apr 25. Clin Gastroenterol Hepatol. 2018. PMID: 29704680

8

TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?

Verstockt B, Verstockt S, Blevi H, Cleynen I, de Bruyn M, Van Assche G, Vermeire S, Ferrante M. Verstockt B, et al. Among authors: verstockt s. Gut. 2019 Aug;68(8):1531-1533. doi: 10.1136/gutjnl-2018-316845. Epub 2018 Jul 14. Gut. 2019. PMID: 30007919 No abstract available.

9

Influence of early adalimumab serum levels on immunogenicity and long-term outcome of anti-TNF naive Crohn's disease patients: the usefulness of rapid testing.

Verstockt B, Moors G, Bian S, Van Stappen T, Van Assche G, Vermeire S, Gils A, Ferrante M. Verstockt B, et al. Aliment Pharmacol Ther. 2018 Oct;48(7):731-739. doi: 10.1111/apt.14943. Epub 2018 Aug 15. Aliment Pharmacol Ther. 2018. PMID: 30109889

10

When IBD is not IBD.

Verstockt B, Vermeire S, Van Assche G, Ferrante M. Verstockt B, et al. Scand J Gastroenterol. 2018 Sep;53(9):1085-1088. doi: 10.1080/00365521.2018.1500637. Epub 2018 Sep 26. Scand J Gastroenterol. 2018. PMID: 30256685

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

176 results

Search Page

Filters